Appropriate Use of Azithromycin in Respiratory Infections

FDA-Approved Respiratory Indications

The American Thoracic Society recommends azithromycin as an appropriate first-line therapy for outpatients with community-acquired pneumonia who have no cardiopulmonary disease and no risk factors for drug-resistant S. pneumoniae 1

Azithromycin is appropriate for subacute forms of purulent maxillary sinusitis, especially after symptomatic treatment failure, with a typical treatment duration of 5 days 3, 4

The American College of Physicians recommends against prescribing azithromycin for patients requiring hospitalization, and suggests considering azithromycin for outpatients with no cardiopulmonary disease and no risk factors for drug-resistant S. pneumoniae 1

Azithromycin is indicated for acute exacerbations of chronic bronchitis when at least two of the Anthonisen triad criteria are present, and may be considered for exacerbation prevention in former smokers ≥65 years with moderate to very severe airflow obstruction on an otherwise optimized regimen 2, 3

The Infectious Diseases Society of America notes that the prevalence of macrolide-resistant S. pneumoniae has been increasing, with 25-50% of strains showing resistance 4
The American Heart Association recommends considering the risk of QT prolongation, which can be fatal in at-risk groups, including patients with known prolongation of the QT interval, history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias or uncompensated heart failure, or concurrent use of drugs known to prolong the QT interval 3, 4, 5, 6
The Centers for Disease Control and Prevention advises against prescribing azithromycin for acute uncomplicated bronchitis, viral upper respiratory tract infections, common cold, or congestive rhinosinusitis, due to the risk of promoting antibiotic resistance 3, 6, 7